

Docket No. 1543.002US1
WD #435630

CLEAN VERSION OF PENDING CLAIMS

COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT
AN INFLAMMATORY RESPONSE
Applicant: David J. Grainger et al.
Serial No.: 09/150,813

17. (Canceled)

20. (Canceled)

22. (Canceled)

34. (Canceled)

41. (Canceled)

42. (Canceled)

43. (Canceled)

44. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Canceled)

CLEAN VERSION OF PENDING CLAIMS

Page 2

Docket No. 1543.002US1

Serial No.: 09/150,813

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Canceled)

59. (Canceled)

60. (Canceled)

61. (Canceled)

62. (Canceled)

63. (New) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

64. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

CLEAN VERSION OF PENDING CLAIMS

Page 3

Docket No. 1543.002US1

Serial No.: 09/150,813

65. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14), wherein the dosage form is linked to a site targeting moiety.

66. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of a peptide Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

67. (New) A method of preventing or inhibiting an indication associated with a chcmokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

68. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

69. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a preslccted physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a pcptide comprising no more than 30 amino acid residues, which peptide

CLEAN VERSION OF PENDING CLAIMS

Page 4

Docket No. 1543.002US1

Serial No.: 09/150,813

comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74, wherein the dosage form is linked to a site targeting moiety.

70. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

71. (New) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

72. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

73. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

CLEAN VERSION OF PENDING CLAIMS

Docket No. 1543.002US1

Serial No.: 09/150,813

Page 5

74. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.